Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × SCLC × Immune Checkpoint Inhibitors × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 26 Carcinoma, Hepatocellular 15 Melanoma 11 Neoplasm Metastasis 10 Neoplasms 8 Esophageal Neoplasms 8 Colorectal Neoplasms 8 Triple Negative Breast Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 7 Nasopharyngeal Carcinoma 7 Head and Neck Neoplasms 7 Stomach Neoplasms 6 Recurrence 6 Pancreatic Neoplasms 5 Esophageal Squamous Cell Carcinoma 5 Carcinoma, Renal Cell 5 Breast Neoplasms 5 Biliary Tract Neoplasms 5 Lung Neoplasms 4 Colonic Neoplasms 4 Advanced NSCLC 4 Urinary Bladder Neoplasms 3 Ovarian Neoplasms 3 Hyperthermia 3 Uterine Cervical Neoplasms 2 Turcot syndrome 2 Solid Tumors 2 Solid Tumor, Adult 2 Solid Cancers 2 Small Cell Lung Carcinoma 2

Interventions

Paclitaxel 2 Etoposide 2 Carboplatin 2 sintilimab 1 atezolizumab 1 apatinib 1 Topotecan 1 Platinum 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07110103 2026-02-27

JACKPOT38

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡